Ketamine for the Treatment of Opioid Use Disorder and Depression

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks. If you are eligible and you decide to enroll in the study, your participation will last approximately 8 weeks, or 2 months.
Epistemonikos ID: af25ed33b3fc3cf13139de2d6d535928c3ac7319
First added on: May 06, 2024